Non-hereditary early onset gastric cancer: An unmet medical need

IF 4 3区 医学 Q1 PHARMACOLOGY & PHARMACY Current Opinion in Pharmacology Pub Date : 2023-02-01 DOI:10.1016/j.coph.2022.102344
Angelica Petrillo , Piera Federico , Gianpaolo Marte , Carlo Liguori , Andreas Seeber , Margaret Ottaviano , Andrea Tufo , Bruno Daniele
{"title":"Non-hereditary early onset gastric cancer: An unmet medical need","authors":"Angelica Petrillo ,&nbsp;Piera Federico ,&nbsp;Gianpaolo Marte ,&nbsp;Carlo Liguori ,&nbsp;Andreas Seeber ,&nbsp;Margaret Ottaviano ,&nbsp;Andrea Tufo ,&nbsp;Bruno Daniele","doi":"10.1016/j.coph.2022.102344","DOIUrl":null,"url":null,"abstract":"<div><p>Gastric cancer (GC) is a lethal disease and the diagnosis in the young population is a major challenge from both individual and social point of views. Early-onset GC accounts for ∼5% of GC; among them, 3% are part of a hereditary syndrome and the majority are sporadic. However, even if the early-onset forms were less frequent in the past, the increasing number in the last decades has improved the interest and awareness of them in the society and in the scientific community. In particular, the different behaviour and characteristics of early-onset GC suggest that it is a completely different entity, which requires a tailored and personalized management. Here we provide an updated overview about non-hereditary early-onset GC, which is an unmet clinical need today, along with future perspectives in this field.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489222001710","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Gastric cancer (GC) is a lethal disease and the diagnosis in the young population is a major challenge from both individual and social point of views. Early-onset GC accounts for ∼5% of GC; among them, 3% are part of a hereditary syndrome and the majority are sporadic. However, even if the early-onset forms were less frequent in the past, the increasing number in the last decades has improved the interest and awareness of them in the society and in the scientific community. In particular, the different behaviour and characteristics of early-onset GC suggest that it is a completely different entity, which requires a tailored and personalized management. Here we provide an updated overview about non-hereditary early-onset GC, which is an unmet clinical need today, along with future perspectives in this field.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非遗传性早发癌症:未满足的医疗需求
癌症是一种致命的疾病,从个人和社会角度来看,年轻人群的诊断是一个重大挑战。早期发作的GC占GC的~5%;其中,3%属于遗传性综合征,大多数为散发性综合征。然而,即使早发性形式在过去不那么常见,但在过去几十年中数量的增加提高了社会和科学界对它们的兴趣和认识。特别是,早发性GC的不同行为和特征表明,它是一个完全不同的实体,需要量身定制和个性化的管理。在这里,我们提供了关于非遗传性早发性GC的最新概述,这是当今尚未满足的临床需求,以及该领域的未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.80
自引率
2.50%
发文量
131
审稿时长
4-8 weeks
期刊介绍: Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.
期刊最新文献
Editorial Board Role of specific CDKs in regulating DNA damage repair responses and replication stress Therapeutic innovations for geographic atrophy: A promising horizon Targeting the soluble epoxide hydrolase pathway as a novel therapeutic approach for the treatment of pain Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1